05814nam 2201729z- 450 991055754620332120210501(CKB)5400000000044145(oapen)https://directory.doabooks.org/handle/20.500.12854/69451(oapen)doab69451(EXLCZ)99540000000004414520202105d2020 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNovel Biomarkers for Heart DiseaseBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20201 online resource (420 p.)3-03943-883-2 3-03943-884-0 Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers.Medicinebicsscacute kidney injuryacute myocardial infarctionAMIaneurysmaortic diseaseaortic regurgitationatrial fibrillationatrial myopathybiomarkerbiomarkerscarbohydrate antigen-125cardiac biomarkerscardiac intensive care unitscardiac magnetic resonance imagingcardiometabolic diseasecardiometabolic riskscardiovascular deathcardiovascular diseasescardiovascular eventscardiovascular riskcardiovascular surgerycatestatincell adhesion moleculeceramidesceruloplasminchronic heart failurechronic kidney diseasecirculating cellscirculating miRNAsCKDcohort studiescoronary artery diseaseCVDdiet qualityechocardiographyejection fractionepicardial adipose tissueepicardial fatepicardial fat volumeFABP3fatty acid-binding protein 3Framingham risk scoreGDF-15GDF8growth differentiation factor 15 (GDF-15)H-FABPhealthy eating indexheart failureheart failure decompensationheart-type fatty acid-binding proteinheart-type fatty acid-binding protein (H-FABP)herat failureHFHFpEFHFrEFhypertensioninflammatory markerKLF4left ventricular adverse remodellingleft ventricular ejection fractionleft ventricular systolic functionliver-type fatty-acid-binding proteinlong-term outcomeslongitudinal strainmagnetic resonance imagingmagnetic resonance spectroscopymetabolic syndromemicroRNAmiRNAmitochondrial DNA (mtDNA)mitochondrial dysfunctionmuscle wastingmyocardial infarctionmyocardial triglyceride contentmyostatinn/aNAFLDNAFLD fibrosis scoreNT-proBNPNYHA functional classobesityolder womenoperative riskoxidative stressPBMCSPentraxin-3plateletsPPCIpregnancy-associated plasma protein-Aprimary preventionreactive oxygen species (ROS)renal dysfunctionrepeated measurementsrisk predictionrisk stratificationsalivasalivary biomarkerssarcopeniasecondary preventionSOCEsoluble suppression of tumorigenicity 2 (sST2)soluble urokinase-type plasminogen activator receptor (suPAR)sST2STEMISTIM1sudden cardiac deathsuPARsynthetic phenotypeT1 mappingTGF-β pathwaythyroid-stimulating hormonetroponinvena contracta areaventricular arrhythmiaventricular tachycardiavery low-density lipoproteinMedicineLichtenauer Michaeledt1287943Lichtenauer MichaelothBOOK9910557546203321Novel Biomarkers for Heart Disease3020593UNINA